Interventional Cardiology

Faxon, David P.; Williams, David O.

doi:10.1161/circulationaha.116.023551

Cited by 22 publications

(9 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronary heart disease (CHD) and atherosclerosis (AS) affect human health worldwide ( 35 ). Interventional cardiovascular therapy has greatly improved the clinical outcomes of patients with CHD ( 36 ). Restoring blood flow is indispensable for rescuing the ischemic myocardium, however, myocardial revascularization also causes damage, known as MI/R injury ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR‑γ and UCP2

2018

View full text Add to dashboard Cite

The present study aimed to investigate whether pretreatment with rosuvastatin (RS) can provide cardioprotection in a myocardial ischemia/reperfusion (MI/R) model. The protective effect of RS on myocardial oxygen-glucose deprivation/reperfusion (OGD/R) injury was also evaluated by upregulating peroxisome proliferator-activated receptor-γ (PPAR-γ). In the present study, MI/R model was established and activities of superoxide dismutase (SOD), lactate dehydrogenase (LDH), creatine kinase-muscle/brain (CK-MB), malondialdehyde (MDA), and troponin I/T were measured. The infarct size was measured using Evans blue staining and cell viability was measured by MTT assay. Reactive oxygen species (ROS) levels were assessed by flow cytometry. Caspase-9, cytochrome c (cyt c), mitochondrial uncoupling protein 2 (UCP2) and PPAR-γ expression levels were detected by reverse transcription-quantitative polymerase chain reaction and western blotting. The results indicated that RS increased SOD activity, and decreased LDH, CK-MB, MDA and troponin I/T activities. The effect of RS was reversed by atractyloside (ATR). RS inhibited myocardial infarct size, downregulated expression of caspase-9 and cyt c and upregulated expression of UCP2 and PPAR-γ by inhibiting ATR. Furthermore, the results indicated that RS promoted cardiomyocyte viability, inhibited LDH release, reduced ROS production, decreased expression of caspase-9 and cyt c, and increased expression of UCP2 and PPAR-γ following OGD/R damage. Therefore, the present study demonstrated that RS protects primary myocardial cells against OGD/R injury by regulating PPAR-γ and UCP2. RS may be a promising therapeutic agent for treatment of MI/R injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR‑γ and UCP2

2018

View full text Add to dashboard Cite

show abstract

“…The improvements in stent design and the development of biocompatible durable polymers, biodegradable polymer, or polymer-free stents have lowered stent thrombosis, surpassing bare metal stents. 4 Biodegradable stents have been intensely studied and, while they have fulfilled some of their promise, late stent thrombosis remains a limitation. 5 The treatment of chronic total occlusions has made remarkable progress, with success rates rising from 50% to 80%-90% now because of advances in antegrade and retrograde techniques.…”

mentioning

confidence: 99%

“…Since transcatheter aortic valve replacement (TAVR) was introduced in 2002, it has grown to an estimated 200 000 procedures worldwide, and it is anticipated to grow to 300 000 by 2020. 4 TAVR has become the standard of care for inoperable and high surgical risk patients with aortic stenosis. Newer lower profile devices have improved safety, with reduced mortality, vascular complications, perivalvular aortic regurgitation, and stroke.…”

mentioning

confidence: 99%

Circulation: Cardiovascular Interventions

Faxon

Leopold

Abbott

et al. 2018

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

“…The current status, new updates, and future directions related to Interventional cardiology have recently been published. [1–4] Interventional procedures are becoming increasingly common and they are now becoming the preferred modes of treatment among patients with specific cardiac disorders. Percutaneous coronary intervention (PCI), which is often associated with earlier hospital discharge, [5] is 1 among the most common interventional procedures which are carried out in PCI-capable centers.…”

Section: Introductionmentioning

confidence: 99%

Application of the SYNTAX score in interventional cardiology

et al. 2017

View full text Add to dashboard Cite

Background:Should the SYNTAX score be integrated in Interventional Cardiology? Should it really be considered as a vital decision-making tool in percutaneous coronary intervention (PCI)? To confirm the importance of this score, we aimed to systematically compare the postinterventional adverse cardiovascular outcomes which were observed in patients who were allotted a low versus a high SYNTAX score.Methods:Randomized controlled trials and observational studies which were published from January 2007 to January 2017 were identified from MEDLINE, EMBASE, and the Cochrane databases using the searched terms ‘SYNTAX score and percutaneous coronary intervention.’ Adverse cardiovascular outcomes were considered as the major endpoints. Risk ratios (RRs) with 95% confidence intervals (CIs) were used as the statistical parameters, and the main analysis was carried out by the RevMan 5.3 software.Results:Sixteen studies with a total number of 19,751 participants (8589 participants with a low versus 11,162 participants with a high SYNTAX score) were included. Current results showed mortality to be significantly higher with a higher SYNTAX score (RR 2.09, 95% CI 1.78–2.46, P = .00001). Cardiac death also significantly favored a low SYNTAX score (RR 2.08, 95% CI 1.66–2.61, P = .00001. Similarly, myocardial infarction, major adverse cardiac events, repeated revascularization, and stent thrombosis were significantly higher following a high SYNTAX score (RR 1.71, 95% CI 1.45–2.03, P = .00001; RR 2.03, 95% CI 1.81–2.26, P = .00001; RR 1.96, 95% CI 1.69–2.28, P = .00001; and RR 3.16, 95% CI 2.17–4.59, P = .00001, respectively). Even when patients with ST-segment elevation myocardial infarction were separately analyzed, a low SYNTAX score was still significantly associated with lower adverse outcomes.Conclusions:This analysis is a confirmatory piece of evidence to show that the application of the SYNTAX score in Interventional Cardiology is apparently relevant. The use of this scoring system to grade patients with coronary artery disease and to further guide for revascularization should be encouraged.

show abstract

Interventional Cardiology

Cited by 22 publications

References 102 publications

Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR‑γ and UCP2

Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR‑γ and UCP2

Circulation: Cardiovascular Interventions

Application of the SYNTAX score in interventional cardiology

Contact Info

Product

Resources

About